Nagasaki Bioventure Company Bio Labo Prepares For Bankruptcy Filing
This article was originally published in PharmAsia News
Executive Summary
According to Japan's private credit agency Teikoku Data Bank, biopharmaceutical venture company Bio Labo, based at Siebold University of Nagasaki, is prepared to file for bankruptcy protection. The company's total debt is estimated to be around ¥700 million. Established in 2003 and led by the university's biologic professor Kenji Kukino, the company aimed to discover new drugs based on generic information obtained from drug companies and received support from the Nagasaki Prefecture. However, a planned joint research facility project with Zhejiang Province, China was delayed in September 2005, which negatively impacted its business. (Click here for more - Japanese language)
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.